These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2527760)

  • 21. Reproducibility of cold provocation in patients with Raynaud's phenomenon.
    Wigley FM; Malamet R; Wise RA
    J Rheumatol; 1987 Aug; 14(4):751-5. PubMed ID: 3668980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
    Wigley FM; Wise RA; Malamet R; Scott TE
    Arthritis Rheum; 1987 Mar; 30(3):281-6. PubMed ID: 2952125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
    O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
    Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vibrotactile sensation and response to nifedipine dose titration in primary Raynaud's phenomenon.
    Challenor VF; Waller DG; Hayward RA; Griffin MJ; Roath OS
    Angiology; 1989 Feb; 40(2):122-8. PubMed ID: 2644877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.
    Gjørup T; Kelbaek H; Hartling OJ; Nielsen SL
    Am Heart J; 1986 Apr; 111(4):742-5. PubMed ID: 3513504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
    Rustin MH; Almond NE; Beacham JA; Brooks RJ; Jones DP; Cooke ED; Dowd PM
    Br J Dermatol; 1987 Dec; 117(6):751-8. PubMed ID: 3322358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute effects of misoprostol on digital circulation in patients with Raynaud's phenomenon.
    Wise RA; Wigley F
    J Rheumatol; 1994 Jan; 21(1):80-3. PubMed ID: 8151594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon.
    Fava A; Wung PK; Wigley FM; Hummers LK; Daya NR; Ghazarian SR; Boin F
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):925-9. PubMed ID: 22275160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prazosin treatment of primary Raynaud's phenomenon.
    Nielsen SL; Vitting K; Rasmussen K
    Eur J Clin Pharmacol; 1983; 24(3):421-3. PubMed ID: 6345178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of pinacidil in patients with primary Raynaud's phenomenon.
    Dompeling EC; Smit AJ
    Vasa Suppl; 1992; 34():34-7. PubMed ID: 1529416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of SR 49059, a V1a vasopressin receptor antagonist, in Raynaud's phenomenon.
    Hayoz D; Bizzini G; Noël B; Depairon M; Burnier M; Fauveau C; Rouillon A; Brouard R; Brunner HR
    Rheumatology (Oxford); 2000 Oct; 39(10):1132-8. PubMed ID: 11035135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Digital pressure and flow measurement upon local cooling in Raynaud's disease. Effect of naftidrofuryl.
    Bounameaux HM; Hellemans H; Verhaege R
    Int Angiol; 1986; 5(1):39-44. PubMed ID: 3734514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-blind, randomised, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon.
    Hirschl M; Katzenschlager R; Ammer K; Melnizky P; Rathkolb O; Kundi M
    Vasa; 2002 May; 31(2):91-4. PubMed ID: 12099151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis.
    Meyrick Thomas RH; Rademaker M; Grimes SM; MacKay A; Kovacs IB; Cook ED; Bowcock SM; Kirby JD
    Br J Dermatol; 1987 Aug; 117(2):237-41. PubMed ID: 3307894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of Raynaud's syndrome with calcium entry blockers].
    Shcherbakov AB; Guseva NG; Mach ES
    Ter Arkh; 1987; 59(4):89-92. PubMed ID: 3296288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Objective benefit of nifedipine in the treatment of Raynaud's phenomenon. Double-blind controlled study.
    White CJ; Phillips WA; Abrahams LA; Watson TD; Singleton PT
    Am J Med; 1986 Apr; 80(4):623-5. PubMed ID: 3515931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.